Multicolumn Countercurrent Solvent Gradient Purification Process

Multicolumn Countercurrent Solvent Gradient Purification Process

Gerard Gach, Chief Marketing Officer at YMC Process Technologies

History shows that in biopharma uptake of innovation is metered, but if the invention has checked all the user need boxes its’ acceptance has an inflection point that resembles a hockey stick (hopefully pointing skyward). MCSGP* has reached that inflection trajectory in 2021 and all indications is that 2022 will see even further large-scale production implementations. The burgeoning interest in oligonucleotide-based therapies by start-ups as well as large global biopharma’s has simultaneously reveled the vast potential therapeutic and curative applications for these molecules but also the need for technologies that solve the yield vs. purity dilemma in manufacturing cost at production scale.


*Multicolumn Countercurrent Solvent Gradient Purification process (MCSGP) is quickly being adopted by large scale CMO’s as a means to accelerate the cost effective production of both oligo and peptide therapies. While heralded as a means to vastly increase yields at the target purity, as the end-users have modeled the incorporation of MCSGP into their production plants, they have been surprised at true impact of this technology on cost reduction not only in the purification steps, but also significant reductions in upstream synthesis and downstream processes. In this year’s World Biopharma Forum 2022, we will be reporting on the present scale of incorporation as well as the MCSGP benefits tallied by its users including:

– Decrease in synthesis batches required (or increase in capacity)

– Reduction in QC analysis and handling

– Potential for reduction in solvent consumption

– A peek into the next iteration of MCSGP that increases both yield and purity.